News and Trends 8 Feb 2018
Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug
Janssen Biotech and Theravance Biopharma will develop together a drug to treat bowel inflammation diseases like ulcerative colitis and Crohn’s disease. Janssen Biotech has set its eyes on a drug candidate being developed by the Irish Theravance Biopharma. Both have entered an agreement to co-develop and commercialize the drug. In exchange, Theravance is getting $100M (€82M) […]